Most eye care ranges are planned as a pair: a serum for the morning & a cream for the night. The sourcing assumption behind that plan is usually wrong, because a serum & a cream are not one formula poured at two viscosities. They are two bases with different oil loads, different gelling systems & different preservation pressure, & approaching them as a single development is why so many first eye ranges ship with one good product & one that creases, balls up or separates in the pack.
This article sets out what actually separates the two formats at the bench, where the eye area forces decisions that other facial products do not face, & how to brief a factory so both products come out of one sampling round instead of three. By the end you should know which of the two to develop first, what can reasonably be shared, & which pack choices quietly lock in the formula before you have approved anything.
Why one formula at two thicknesses does not work
The tempting shortcut is to take a cream base & thin it down. Thinning a cream does not produce a serum; it produces an unstable cream. The thickener that gave the cream its body is diluted below the level at which it builds a network, so the emulsion loses its yield value & starts to separate in the pack within weeks. What looked like a saving turns into a stability failure that only appears after the samples were signed off.
The reverse direction fails differently. A serum thickened into a cream needs a different emulsifier balance & often a different oil phase, because the emulsifier that holds a light fluid cannot carry the oil load a cream needs. Adding oil to a serum usually gives something greasy & grainy rather than rich & cushioning, & the texture never fully recovers.
The practical consequence is that the two formats should be briefed as two projects that share a direction, not as one project with two outputs. What is shared is the positioning & the ingredient story. The base architecture, the emulsifier, the thickener & often the preservative are separate decisions, & factories price them separately for the same reason.
What actually separates the two formats
A serum is usually a low-oil or oil-free system. Its viscosity comes from a water-phase gelling agent such as a carbomer, an acrylate, xanthan or a cellulose derivative, & its skin feel comes from humectants & light emollients. It spreads fast, it dries or absorbs rather than sitting on the surface, & it is judged mostly on the first minute of wear.
A cream is an emulsion with a real oil phase, stabilised by an emulsifier pair & built for a slower, cushioning application. Its thickness comes from the oil phase & the emulsifier system rather than from a gum, which is why a cream can feel rich without feeling sticky. It is judged over the first hour, under makeup & on reapplication.
The sourcing consequence is that the same active rarely behaves the same way in both. A dispersion that looks even in a cream can settle or feel gritty in a thin gel, & a water-soluble humectant that gives a cream its glide can make a serum tacky. Ask for each active to be reviewed in both bases rather than inheriting one approval on the strength of the other.
What the eye area changes about the formula
The eye area is a small surface with thin skin, a lash line, a tear film nearby & a user who applies the product with a fingertip that has just touched the rest of the face. Every one of those facts has a formulation consequence, & together they narrow the design space more than most brands expect.
In practice that means a lower tolerance for fragrance & for volatile solvents, a preservative system chosen for a product that will pick up contamination in use, & a much tighter limit on particulates, because a scratchy particle near the eye is remembered for a long time. A heavy load of anything with a strong sensory signature rarely survives an eye-area panel, however well it reads on an ingredient list.
Dose matters more here too. A face cream is judged across 50 ml; an eye product across 10 to 15 ml applied in a fraction of the volume. A texture that feels pleasant in a pea-sized amount on the cheek can be far too heavy or too firming in a small touch along the orbital bone.
Dose per application & the economics of a small pack
Eye care is the clearest case where the unit price is driven by the pack rather than by the bulk. A 15 ml tube carries roughly a third of the fill of a 50 ml face product but usually sells at a premium, so the margin is decided by the component cost, the fill accuracy & the decoration long before the ingredient list enters the conversation.
Small fills are also less forgiving. At 15 ml a fill tolerance that is invisible on a 200 ml bottle becomes a visible overfill or underfill against the label claim, & the loss shows up directly in the unit cost. Ask what tolerance the factory holds at your fill volume, & whether the filling line is set up for small bottles or adapted down from a larger format.
Where the two formats sit in one range, the cost structure is asymmetric. The serum is often the cheaper fill in the more expensive component, & the cream the reverse. Planning the price ladder before sampling avoids the awkward discovery that the two products cannot be priced apart on the shelf without one of them looking overpriced.
Choosing the base architecture before the ingredients
There are four architectures an eye product usually lands in: a water gel, a gel-cream, a classic emulsion & an anhydrous balm or oil. Each one sets what the product can do sensorially & what it can carry, & the choice is much harder to reverse than an ingredient change.
A water gel gives the fastest, lightest feel & the strongest fresh signal, at the cost of a formula that is harder to preserve & quicker to dry in the pack. A gel-cream is the compromise most brands choose for a morning eye product, giving glide without an oil film. A classic emulsion is the safer route for a night product & for anything with a lipid-based story. An anhydrous base carries oil-soluble ingredients well & needs almost no preservation, but it will not deliver the cold, watery sensation that most eye serum buyers expect.
The mistake to avoid is choosing the architecture from a competitor's product description. A listing that calls a product a gel serum may be describing any of the four. Send the factory the sensory target in words, meaning the speed of absorption, the film & the slip, rather than a claim about the format.
How the same actives behave in each base
Ingredient stories travel well in marketing & badly in formulation. Caffeine, peptides, niacinamide, panthenol, hyaluronic acid at various molecular weights & ceramides are all common eye-care names, & each one has a base it prefers.
Water-soluble actives usually sit comfortably in a gel or a gel-cream, but they need a buffered pH window & a chelator to stay clear. Lipid-soluble actives want the oil phase of an emulsion or an anhydrous base, & they behave badly in a gelled water system, where they can cloud the gel or separate out. Peptides in particular are sensitive to pH drift, to certain preservatives & to order of addition, which is why a peptide list copied from one product into a new base can fail without any single ingredient being wrong.
The useful request to a factory is not "include this list" but "tell me which of these carry comfortably into each base, & what has to change if one of them does not". That conversation costs one email & saves one sampling round.
Preservation, pH & the two-format microbial question
Both formats contain water & both therefore need a preservation strategy, but the risk profile differs. A thin gel has high water activity & low viscosity, which makes it easy to contaminate & easy to spread a contaminant through the pack. A cream has a higher oil content & a more structured matrix, which slows contamination but also hides it, because a spoiled cream can look & smell normal for longer.
The pH window is the second difference. Many gelling agents need a pH that suits their thickening mechanism, & several common preservative systems are only effective in their acid form, so the two requirements have to be reconciled rather than chosen one at a time. A serum thickened at the pH the gum prefers may sit just outside the window where the preservative actually works.
For a brand, the question worth asking at the brief stage is what the preservation strategy is based on. A challenge test on the finished formula, run in the actual pack, is the evidence. A statement that the preservative is mild & well established is not, & it is worth knowing which of the two you have been given.
When the two products can share a base
Full separate development is the cleanest route & the most expensive. There is a middle path: build one base & derive the second from it, accepting a shorter development cycle in exchange for less freedom in the second formula.
The realistic sharing cases are a gel & a gel-cream built from the same gelling system at two concentrations, or a cream & a richer night version built from the same emulsifier pair. What rarely shares well is a water gel & an anhydrous base, because beyond the ingredient story they have almost nothing in common.
If the range is planned as a set, say so at the brief stage. A factory that knows a second format is coming can leave the first architecture in a shape that accepts the second version, which is far cheaper than rebuilding later. Even a second product expected a year out is worth mentioning, because it changes the emulsifier shortlist today.
Sampling & testing two formats in parallel
Two formats mean two stability studies, two compatibility checks & two sensory panels, & the temptation is to run them one after the other to save cost. That is usually the wrong trade, because the two studies answer different questions & running them together keeps the launch on a single critical path.
The tests worth pairing are the accelerated study & the pack compatibility check, since a formula that survives heat but attacks its own tube has not passed anything useful. A freeze-thaw cycle is worth adding to both, because a gel & an emulsion show cold damage differently: the gel goes cloudy or grainy, the emulsion separates.
The sensory panel should be run on both products, with the same instruction & the same amount. A panel that tests the serum from a pump dose & the cream from a fingertip scoop produces two results that cannot be compared, & the comparison is the whole reason for testing them together.
Pack pairing & the choices that lock in the formula
The pack is part of the formulation decision in eye care more than in most categories, because the fill volume is small & the application area is sensitive. A pump that delivers a fixed dose suits a serum that has to be metered. A tube suits a cream the user will judge by the amount they can squeeze. A pot suits a thick balm & punishes a light fluid.
A pot is the cheapest component & the hardest on the formula: the bulk meets air & fingers on every use, so the preservative load & the in-use test have to assume that. A tube protects better & still allows a precise nozzle, which matters when the product has to run along a lash line without flooding. An airless pump protects the bulk best & fixes the dose, at a higher component cost & with a priming behaviour that should be checked before launch rather than after.
Because pack & formula interact, the pack should be chosen before the first sample is approved. A formula optimised in a pot & then moved into an airless pump often needs its viscosity rebalanced, because a pump has an upper limit on viscosity as well as a lower one.
Eye serum & eye cream compared across the sourcing decisions
The table below puts the two formats side by side against the decisions a brand actually has to make, so the differences surface while the brief is being written rather than during sampling.
| Decision | Eye serum | Eye cream | What it changes in the project |
|---|---|---|---|
| Base architecture | Low-oil or oil-free, gelled water phase | Emulsion with a real oil phase | Two bases to develop, not one |
| Thickening route | Gum, acrylate or cellulose in water | Oil phase with an emulsifier pair | Viscosity cannot be moved between them |
| Skin feel target | Fast, light, little residue | Cushioning, slower to set | Two sensory panels, two benchmarks |
| Pack it suits | Airless mini pump, dropper, roller | Tube, pot, mini airless | Pack choice feeds back into viscosity |
| Typical fill volume | Usually 10 to 20 ml | Usually 15 to 30 ml | Small fills cut both ways on unit cost |
| Preservation pressure | High, high water activity | Moderate, oil phase slows ingress | Two challenge tests, both in the real pack |
| Cold & heat behaviour | Goes cloudy or grainy | Separates or grains | Freeze-thaw needed on both |
| Usual day part | Morning, often under makeup | Night, or very dry markets | Selling logic decides which launches first |
The rows describe the usual pattern rather than a fixed rule. A very low-oil cream & a very rich serum can end up closer to each other than either is to the middle of its own category, which is why the sensory target matters more than the word on the jar. Read the table as the order in which decisions have to be made, not as a specification.
What to put in the brief
Write the brief as one range with two products, & say explicitly which one launches first. That single statement changes how the factory sequences the work, because the architecture of the first product can be shaped to accept the second. Then give the sensory target in plain words, since it is the one input a formulator cannot infer from an ingredient list.
- Which format launches first, & how soon the second one follows.
- The sensory target in words: absorption speed, film, slip & residue.
- The actives you plan to name on pack, & the base you expect each in.
- The fill volume & pack type you have in mind for each format.
- The markets you will sell into, & any labelling duties that follow.
- Whether fragrance is included, & your position on allergen declaration.
- The shelf life you intend to claim, & whether real-time data must exist first.
- The expected first order volume per product, & whether a low first run is possible.
Then agree the sampling sequence. The efficient path for a two-product range is one base sample per format, a second round to confirm the actives behave, & a golden sample of each held by both sides. Brands that approve the cream & assume the serum will follow usually pay for the assumption twice: once in a second development round, & again in a launch date that slips past the season they were buying for.
Where our capability fits
We develop eye care as a pair rather than as a single product, so the gel & the cream are built with one ingredient story, one testing timeline & one filling schedule. The base architectures are set against the sensory target you give us, the preservation route is chosen for the pack you intend to use, & the bulk is filled on lines set up for small volumes where the fill tolerance is the difference between margin & loss.
We work with brands on private label (your brand on a proven base), OEM/ODM contract manufacturing & full custom formula development, & we will say at the brief stage which parts of an eye range can share a base & which cannot. Our adjacent face-care lines include a hyaluronic acid serum & a firming face cream, both produced under the same batch record & retention discipline we apply to eye care.
Tell us which format you want to launch first & what you want the user to feel, & we will come back with a base proposal for each format, the pack that suits it & the testing it implies. Start at our inquiry page, email capsulebiotech@163.com, or message the right team on WhatsApp: Capsule Series (capsules only) +86 158-7655-5319, Cosmetics Series (serum, hair care, body care, fragrance) +86 158-7655-5319. For the formulation background, see our guide to eye cream formulation & our note on pH & viscosity control.
General manufacturing information, not regulatory or legal advice. Ingredient limits, labelling duties & claim wording rules vary by market & by product, & the applicable requirements should be confirmed for each destination before a product is placed on sale.